ARCHIVES

Guest Editorial: The Walue of Quality of Life Data In Judging Patient Benefit: experts Respond To ODAC

This article is from The Cancer Letter archive.

Vol. 25 No. 33 | September 3, 1999

Download PDF Visit The Full Archive

Related Articles

FDA Committee Okays High Dose Methotrexate, Mitxantrone In ANL; reverse Breast Cancer Vote

December 11, 1987

OMB reviewing Administration’s Reauthorization Bill; NCI Special Authority Probably Will Remain

April 15, 1988

NCI Audit Finds “Low Quality” Research At Calif. Foundation

June 17, 1994

SWOG Restarts Gynecologic Malignancies Committee.

May 16, 2008

Bristol-Myers Adds UCLA, Fox Chase To Grants Program

April 12, 1985

President Obama Signs FDA User Fee Act Into Law

July 13, 2012